Home › Companies › Monte Rosa Therapeutics, Inc. › 2025-2026
At Monte Rosa Therapeutics, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 67 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 854 separate fund positions. On the most widely held item on that ballot — To elect three Class II director nominees to our board of directors, to serve until the… — FOR was 99% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Monte Rosa Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Monte Rosa Therapeutics, Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 11, 2026: 4 items on Monte Rosa Therapeutics, Inc.’s Form 8-K, filed June 11, 2026: 1 approved · 3 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Monte Rosa Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Monte Rosa Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Andrew Schiff, M.D. | 71,409,008 | -- | -- | 741,197 | 3,128,885 | 99% | Not verified | — |
| Elect Director: Chandra P. Leo, M.D. | 71,469,933 | -- | -- | 680,272 | 3,128,885 | 99.0% | Not verified | — |
| Elect Director: Anthony Manning, Ph.D. | 56,995,916 | -- | -- | 15,154,289 | 3,128,885 | 79% | Not verified | — |
| 2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm | 75,171,524 | 57,950 | 49,616 | -- | 0 | 99.9% | Approved | — |
Source: Monte Rosa Therapeutics, Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.
Each item below shows how the 67 asset managers that disclosed a Monte Rosa Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Andrew Schiff, M.D.
Monte Rosa Therapeutics, Inc.’s own tally for this item (“Elect Director: Andrew Schiff, M.D.”): 71,409,008 for, 741,197 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 15,926,460 for, 94,094 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 4,977,606 | 0 | 0 | 0 | For |
| American Century | 2,582,410 | 0 | 0 | 0 | For |
| Vanguard | 2,167,422 | 0 | 1 | 4,152 | For |
| BlackRock | 1,272,196 | 0 | 0 | 0 | For |
| State Street | 763,174 | 0 | 0 | 1,013 | For |
| First Trust | 588,808 | 0 | 0 | 0 | For |
| Charles Schwab | 543,754 | 0 | 0 | 0 | For |
| Fidelity | 436,658 | 0 | 0 | 0 | For |
| Allspring | 346,268 | 0 | 0 | 0 | For |
| Northern Trust | 308,444 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 220,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 200,000 | 0 | 0 | 0 | For |
| Equitable | 129,108 | 0 | 0 | 40,360 | Mixed |
| Victory Capital | 155,909 | 0 | 0 | 0 | For |
| Brighthouse | 113,229 | 0 | 0 | 0 | For |
| TIAA | 104,976 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,125 | 0 | 0 | 1,541 | For |
| Pacific Life | 72,422 | 0 | 0 | 0 | For |
| Putnam | 67,925 | 0 | 0 | 0 | For |
| Voya | 64,870 | 0 | 0 | 0 | For |
| John Hancock | 62,366 | 0 | 0 | 1,139 | For |
| ProShares | 57,745 | 0 | 0 | 0 | For |
| Transamerica | 48,355 | 0 | 0 | 0 | For |
| MFS | 46,882 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 41,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Chandra P. Leo, M.D.
Monte Rosa Therapeutics, Inc.’s own tally for this item (“Elect Director: Chandra P. Leo, M.D.”): 71,469,933 for, 680,272 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 15,948,613 for, 71,942 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 4,977,606 | 0 | 0 | 0 | For |
| American Century | 2,582,410 | 0 | 0 | 0 | For |
| Vanguard | 2,168,783 | 0 | 0 | 2,791 | For |
| BlackRock | 1,272,196 | 0 | 0 | 0 | For |
| State Street | 763,174 | 0 | 0 | 1,013 | For |
| First Trust | 588,808 | 0 | 0 | 0 | For |
| Charles Schwab | 543,754 | 0 | 0 | 0 | For |
| Fidelity | 436,658 | 0 | 0 | 0 | For |
| Allspring | 346,268 | 0 | 0 | 0 | For |
| Northern Trust | 308,444 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 220,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 200,000 | 0 | 0 | 0 | For |
| Equitable | 129,108 | 0 | 0 | 40,360 | Mixed |
| Victory Capital | 155,909 | 0 | 0 | 0 | For |
| Brighthouse | 113,229 | 0 | 0 | 0 | For |
| TIAA | 104,976 | 0 | 0 | 0 | For |
| Lincoln Financial | 77,125 | 0 | 0 | 1,541 | For |
| Pacific Life | 72,422 | 0 | 0 | 0 | For |
| Putnam | 67,925 | 0 | 0 | 0 | For |
| Voya | 64,870 | 0 | 0 | 0 | For |
| John Hancock | 62,366 | 0 | 0 | 1,139 | For |
| ProShares | 57,745 | 0 | 0 | 0 | For |
| Transamerica | 48,355 | 0 | 0 | 0 | For |
| MFS | 46,882 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 41,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect three Class II director nominees to our board of directors, to serve until the Company's 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Anthony Manning, Ph.D.
Monte Rosa Therapeutics, Inc.’s own tally for this item (“Elect Director: Anthony Manning, Ph.D.”): 56,995,916 for, 15,154,289 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 10,097,753 for, 5,922,791 withheld, 12 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 4,977,606 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 0 | 2,582,410 | Withhold |
| Vanguard | 2,170,202 | 0 | 12 | 1,361 | For |
| BlackRock | 1,272,196 | 0 | 0 | 0 | For |
| State Street | 1,577 | 0 | 0 | 762,610 | Withhold |
| First Trust | 0 | 0 | 0 | 588,808 | Withhold |
| Charles Schwab | 543,754 | 0 | 0 | 0 | For |
| Fidelity | 436,658 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 0 | 346,268 | Withhold |
| Northern Trust | 0 | 0 | 0 | 308,444 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 220,000 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 200,000 | Withhold |
| Equitable | 129,108 | 0 | 0 | 40,360 | Mixed |
| Victory Capital | 0 | 0 | 0 | 155,909 | Withhold |
| Brighthouse | 92,043 | 0 | 0 | 21,186 | Mixed |
| TIAA | 104,976 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 78,666 | Withhold |
| Pacific Life | 23,563 | 0 | 0 | 48,859 | Mixed |
| Putnam | 67,925 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 64,870 | Withhold |
| John Hancock | 46,526 | 0 | 0 | 16,979 | Mixed |
| ProShares | 0 | 0 | 0 | 57,745 | Withhold |
| Transamerica | 48,355 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 46,882 | Withhold |
| HUSSMAN INVESTMENT TRUST | 41,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and
Monte Rosa Therapeutics, Inc.’s own tally for this item (“2. Ratification of Appointment of the Company's Independent Registered Public Accounting Firm”): 75,171,524 for, 57,950 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of the Company's Independent Registered Public Accounting Firm The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 67 asset managers below reported 16,020,555 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| T. Rowe Price | 4,977,606 | 0 | 0 | 0 | For |
| American Century | 2,582,410 | 0 | 0 | 0 | For |
| Vanguard | 2,171,574 | 0 | 0 | 0 | For |
| BlackRock | 1,272,196 | 0 | 0 | 0 | For |
| State Street | 764,187 | 0 | 0 | 0 | For |
| First Trust | 588,808 | 0 | 0 | 0 | For |
| Charles Schwab | 543,754 | 0 | 0 | 0 | For |
| Fidelity | 436,658 | 0 | 0 | 0 | For |
| Allspring | 346,268 | 0 | 0 | 0 | For |
| Northern Trust | 308,444 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 220,000 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 200,000 | 0 | 0 | 0 | For |
| Equitable | 169,468 | 0 | 0 | 0 | For |
| Victory Capital | 155,909 | 0 | 0 | 0 | For |
| Brighthouse | 113,229 | 0 | 0 | 0 | For |
| TIAA | 104,976 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,666 | 0 | 0 | 0 | For |
| Pacific Life | 72,422 | 0 | 0 | 0 | For |
| Putnam | 67,925 | 0 | 0 | 0 | For |
| Voya | 64,870 | 0 | 0 | 0 | For |
| John Hancock | 63,505 | 0 | 0 | 0 | For |
| ProShares | 57,745 | 0 | 0 | 0 | For |
| Transamerica | 48,355 | 0 | 0 | 0 | For |
| MFS | 46,882 | 0 | 0 | 0 | For |
| HUSSMAN INVESTMENT TRUST | 41,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. All 67 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,479,418 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | T. Rowe Price | 5.89% |
| 2 | American Century | 3.06% |
| 3 | Vanguard | 2.57% |
| 4 | BlackRock | 1.51% |
| 5 | State Street | 0.90% |
| 6 | First Trust | 0.70% |
| 7 | Charles Schwab | 0.64% |
| 8 | Fidelity | 0.52% |
| 9 | Allspring | 0.41% |
| 10 | Northern Trust | 0.37% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Baker Bros. Advisors LP | 10.51% | 13G |
| Entities affiliated with New Enterprise Associates | 9.11% | DEF14A |
| T. Rowe Price | 7.95% | 13F |
| New Enterprise Associates 17, L.P. | 7.92% | 13D |
| Dimension Management, L.P. | 7.71% | 13G |
| Entities affiliated with Dimension Capital | 7.71% | DEF14A |
| BlackRock | 6.67% | 13F |
| BVF PARTNERS L P/IL | 6.02% | 13G |
| Chen Yu | 5.47% | 13G |
| Vestal Point Capital, LP | 5.45% | 13G |
Percentages above are of 84,479,418 shares outstanding, as reported by Monte Rosa Therapeutics, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Monte Rosa Therapeutics, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Monte Rosa Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Monte Rosa Therapeutics (GLUE) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/monte-rosa-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.